Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to discuss 2 Growth stocks to Buy with MASSIVE Upside potential.

2 extracted signals · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
09 Apr 2026, 22:51 UTC
Recorded by Tahlil Plus
18 May 2026, 20:24 UTC
Video preview for Friends! In this video, I'm going to discuss 2 Growth stocks to Buy with MASSIVE Upside potential.
Source overview

AI-generated source summary

The stock market analysis highlights two growth stocks, GRAB and DUOL, with potential for upside. GRAB is considered undervalued based on its P/E ratio and free cash flow, despite recent underperformance. DUOL, despite a recent stock price drop, is guided by strong future growth expectations, with the company's CEO indicating confidence in achieving 100 million daily active users by 2028 through a focus on diversifying its user base into chess, math, and music. The analysis suggests that GRAB's valuation and growth potential make it an attractive investment. DUOL's forward guidance points to significant revenue growth and market share expansion.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
2
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
1
Cancelled, invalid or excluded
Resolved success
100%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    2 eligible signals linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.3
Tracked signals
327
Historical success
34.1%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail